FDA Extends Enforcement Discretion On Free Phytosterol Health Claims
This article was originally published in The Pink Sheet Daily
Firms now have a year to drop claims of reduced risk for coronary heart disease for free-form phytosterols, which are more frequently used to make supplements because they are less bulky and facilitate the production of smaller, easier-to-swallow pills, or reformulate their products.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.